ORTHOX HOLDINGS LIMITED

• ⚠

  Confirmation statement overdue

  Due 2026-06-26.

• ◆

  Material uncertainty over going concern

  We draw your attention to Note 1.3 in the financial statements, which indicates that due to adverse results on recent clinical trials, the company's ability to continue as a going concern is reliant upon the results of the ongoing investigation and cost restructuring. These conditions indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.

• ·

  Going-concern uncertainty disclosed

• ·

  Negative shareholders' funds

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. The Δ column is the change from the prior filed period as a percentage of |prior|; lines a company doesn't report show —. About these numbers

Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Abridged

Yes — abridged accounts (limited disclosure)

Auditor

Richardsons

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw your attention to Note 1.3 in the financial statements, which indicates that due to adverse results on recent clinical trials, the company's ability to continue as a going concern is reliant upon the results of the ongoing investigation and cost restructuring. These conditions indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern.”

Group structure

1. ORTHOX HOLDINGS LIMITED · parent
   1. Bounce Biomedical Limited (formerly Orthox Limited) 100% · England and Wales

Significant events

• “Following adverse clinical results on the FFLEX trial in 2023, the subsequent cost rationalisation process has continued to reduce company expenditure significantly and with the award of a new £100k NMIP grant to Orthox from Innovate UK in 2026, a revised cashflow forecast projects funds will run to at least the end of Q3 2027. In addition, following the licensing of IP related to cartilage repair material from Imperial College London and the award of a KTP grant from Innovate UK to Imperial and Orthox then the Wellcome Trust have provided a letter of comfort confirming that they will not call in their loan until June 2028 at the earliest.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

2

last 12 months

Capital events

2

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.